My insurance company no longer covers my medicine. What are my options?

People often choose a medical insurance plan because they know it will cover medication they are currently receiving. In some cases, such as with biologics or oncology medications, out-of-pocket cost is simply not feasible for most families.

When an insurance company stops covering one drug and recommends a different one, it is commonly called a formulary change or exclusion. The decision is often financial.

Brand name drugs are often more expensive than generic alternatives, and for certain high-cost therapies, that difference can be thousands of dollars for insurers.

Insurers often argue that generics or biosimilars have similar active ingredients, strength, dosage, and administration method, and therefore should produce similar outcomes.

It is tempting to assume that medicines with the same dose and active ingredient will always work the same way, but that is not always true in practice.

For some patients, inactive ingredients in a generic can trigger different side effects or tolerability issues than the brand medication.

In other cases, patients are simply not able to control their condition as well after switching, even when the medication appears equivalent on paper.

Biologics are one class where this concern often comes up. Many alternatives are biosimilars, not exact copies. Because biologics are complex to manufacture, biosimilars are approved based on a high similarity standard and switching studies, rather than being chemically identical in every way.

In some situations, brand drugs may also be more affordable for the patient because manufacturer copay assistance can reduce out-of-pocket costs. Not all biosimilars offer comparable copay programs.

In biologic treatment, decision-making can become complicated. Most people assume the doctor and patient make the final choice because they best understand the condition and treatment history.

In reality, insurers can impose coverage rules that require a biosimilar before approving a brand-name drug.

In some states and situations, pharmacies may also substitute a biosimilar unless the prescriber clearly documents that the brand is medically necessary.

Yes. There are several steps you and your provider can take to challenge non-medical generic or biosimilar switching.

If you plan to appeal internally or externally, preparation makes a major difference.

State law can materially affect your strategy and timelines. A few examples:

Illinois: Public Act 100-1052 is designed to prevent mid-year insurance "bait-and-switch." It prohibits insurers from removing a drug or moving it to a higher-cost tier during the plan year when a patient is stable on that therapy. Reference: U.S. Pain Foundation on Illinois Public Act 100-1052.

California: AB 347 requires plans to expeditiously grant step therapy exceptions when a provider submits proper justification and clinical support. It also allows appeals when an exception request is denied.

Kentucky: Senate Bill 140 (2022) requires response to step therapy exception requests within 48 hours, after which requests may be treated as granted. The law also recognizes exception circumstances such as contraindications and patients stable on current therapy. Reference: Kentucky Senate Bill 140.

Arizona: Insurers must respond within 72 hours for standard requests and 24 hours for urgent cases, with deemed approval in specified situations if deadlines are missed. Exceptions can include medical necessity, ineffectiveness, or comorbidity concerns.

At least 30 states have passed laws related to formulary exclusions or step therapy protections. The challenge is knowing exactly how your state rules apply to your case.

Health advocates at guidemyclaim.com can help you understand your rights and build a more effective appeal strategy.

You can speak with an advocate for free by filling out the form at the top of this post or by emailing support@guidemyclaim.com.

You should not have to navigate healthcare complexity alone.